Fasikl Secures $18.3M in Series A+ Venture Capital Investment

(MINNEAPOLIS, Minn.) September 10, 2024 – Fasikl closes an $18.3 million A+ round investment to develop AI-driven therapeutic technologies. The funds will be allocated to R&D and clinical trials for expanding indications. The round is co-led by iSeed and Tailwinds Ventures.